



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

November 3, 2025

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai – 400 001
Scrip Code: 500680

The Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Board Meeting to consider and approve the Unaudited Financial Results for the quarter and half year ended September 30, 2025.

Ref.: Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on **Wednesday, November 12, 2025** *inter alia*, to consider, approve and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025.

Further, pursuant to the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading), Regulations, 2015 and in accordance with “Pfizer Limited – Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders”, the Trading Window for dealing in shares of the Company has been closed from Tuesday, September 30, 2025 (close of business) till 48 hours after the said Unaudited Financial Results are made public on November 12, 2025.

Request you to please take the above on record.

Thanking you,

Yours truly,
For **Pfizer Limited**

Prajeet Nair
Director – Corporate Services & Company Secretary

Cc: National Securities Depository Limited (NSDL)
Central Depository Services (India) Limited (CDSL)
KFin Technologies Limited